Journal of Clinical Oncology
Articles in this Issue
Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression and ctDNA profiles.
e16041 Background: Immunotherapy and chemotherapy combinations have become the standard treatment of HER2-negative advanced gastric cancer (AGC). However,...
Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: Results from an international cohort study.
10509 Background: Pathogenic/likely pathogenic variants (P/LPVs) in the BRCA1 or BRCA2 genes significantly increase the risk of de...
Safety and efficacy of pembrolizumab and epacadostat combination therapy in metastatic epithelial-derived cancers: A systematic review and meta-analysis of randomized controlled trials.
e15128 Background: In cancer patients, immunotherapy is a progressive treatment that uses the body’s immune system to fight. Pembrolizumab is a programmed...
Perilipin 5 as mediator of high-fat diet-induced hepatocellular carcinoma immune escape by stabilization of PD-L1 expression.
e14600 Background: Obesity is a significant risk factor for hepatocellular carcinoma (HCC), but the precise mechanisms are unclear. Perilipin 5 (PLIN5) is...
Immune-related pathologic response (irPR) features and immunotherapeuticresponse score (ITRS) to predict survival following neoadjuvant combined immunotherapy in hepatocellular carcinoma.
e16312 Background: A prospective, single-arm, open-label exploratory, phase II study (ChiCTR2000035901) aims to explore the safety and efficacy of Sintili...
Utilizing TP53 mutation status and initial disease burden at presentation to risk-stratify patients with advanced EGFR-mutated NSCLC treated with osimertinib.
e20663 Background: There are multiple FDA approved first line options for stage IV EGFR mutated NSCLC but no clear prognostic models to guide treatment. T...
Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study).
11509 Background: There was limited therapeutic advancement for decades for patients (pts) with relapsed and refractory (R/R) osteosarcoma. Pts with R/R o...
Cardiovascular outcomes in African American patients with multiple myeloma: The role of amyloidosis.
e19566 Background: Amyloidosis, particularly light-chain (AL) amyloidosis, is a rare but serious complication of multiple myeloma (MM) that can significan...
Disparities in exercise referral practices and barriers among oncologists in public and private institutions in Latin America.
1629 Background: Exercise offers significant benefit for patients with cancer, improving physical function, quality of life, and treatment-related outcome...
Cardiovascular risk factor severity and adverse cardiovascular events: A report from the Childhood Cancer Survivor Study (CCSS).
12055 Background: Among survivors of childhood cancer, more severe grades of CVRFs are associated with increased risk for adverse cardiovascular events (A...
Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.
9518 Background: Metastatic melanoma refractory to immune checkpoint inhibitors (ICI) remains a significant challenge. Adoptive Cell Transfer of Tumor-Inf...
Effect of a surgery-based comprehensive treatment on prognosis of stage IIIC cervical squamous carcinoma: A single center retrospective study.
e17520 Background: Stage IIIC of cervical cancer is when lymph node metastasis occurs. Lymph node metastasis is one of the most important prognostic facto...
Vasculogenic mimicry as a potential indicator of drug resistance and prognosis in renal cell carcinoma.
4551 Background: Patients with advanced metastatic renal cell carcinoma (RCC) often develop resistance to tyrosine kinase inhibitors (TKIs). Vasculogenic...
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation.
8098 Background: Debio 0123 is an oral, brain-penetrant, highly selective WEE1 inhibitor. WEE1 inhibition leads to S phase...
Evaluating the applicability of axillary surgery omission in real-world breast cancer patients: Insights from an INSEMA-eligible cohort.
e12580 Background: The INSEMA trial demonstrated noninferiority of omitting axillary surgery compared to sentinel lymph node biopsy (SLNB) in clinically n...
Correlative and spatial transcriptomic analysis of olaparib and durvalumab in patients with recurrent/refractory <i>IDH</i> -mutant gliomas.
2075 Background: Combination of immune checkpoint and PARP inhibition has potential synergistic effects in IDH mt gliomas in pre-c...
Association of rurality with guideline-concordant survivorship care receipt among Medicare beneficiaries with colorectal cancer.
e23130 Background: Rural-urban disparities strongly impact colorectal cancer screening, diagnosis, and treatment, creating challenges that persist beyond...
Quantifying the clinical impact of tissue reflex testing for liquid biopsy <i>ESR1</i> mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
1065 Background: ESR1 mutations ( ESR1 mut) commonly drive acquired resistance to estrogen deprivation by aromatase in...
Outcomes of patients with stage II/IIIA urothelial bladder cancer treated with systemic therapy: A 13-year single-center experience.
e16586 Background: Optimal management of stage II/IIIA urothelial bladder cancer (UBC) continues to evolve, with neoadjuvant chemotherapy (NAC) followed b...
Real-world assessment of breast cancer risk following hormonal therapy in endometriosis: A Global Collaborative Network propensity score matched analysis.
11143 Background: Research suggests endometriosis, an estrogen-dependent condition, may be a potential risk factor for breast cancer (BC) development. Whi...
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.
TPS6113 Background: HPV-negative head and neck squamous cell carcinoma (HNSCC) is an aggressive disease characterized by h...
Targeting focal adhesion kinase to mitigate hepatotoxicity induced by PD-1 inhibition with or without KRAS G12C suppression.
e14597 Background: Although PD-1 antibodies exhibit significant therapeutic potential, their clinical utility is often constrained by substantial liver to...
Trastuzumab deruxtecan (T-DXd) monotherapy in advanced HER2-positive or HER2-low/ultralow breast cancer: An updated pooled analysis of prospective clinical trials.
e13103 Background: The efficacy and safety of T-DXd have been established in patients with advanced HER2-positive or HER2-low/ultralow breast cancer. We a...
miRNA-mRNA regulatory network analysis of tumor-associated MSCs and cancer-associated fibroblasts (CAFs) in lung cancer microenvironment.
e20521 Background: Cancer is a complex disease involving not only cancer cells, but also the surrounding microenvironment, which includes various cells, s...
Preclinical Project Optimus dose escalation of SN-38 pro-drug PCS11T.
e15023 Background: FDA’s Project Optimus initiative on optimizing the dose of drugs used for the treatment of cancer emphasizes the need to justify the do...